Table 1.

Affinity prediction for tumor-associated antigens from the cancer antigenic peptide database

Mutation		Tumor specific		Differentiation		Overexpressed
Seq	Aff (nM)	Seq	Aff (nM)	Seq	Aff (nM)	Seq	Aff(nM)
HLA-A*0201
FLDEFMEGV	2.86	MLAVISCAV	6.18	IMIGVLVGV	3.61	FMNKFIYEI	2.34
VVMSWAPPV	5.04	KVLEYVIKV	6.23	RLMKQDFSV	4.23	RLMNDMTAV	3.39
GLFGDIYLA	6.07	GLYDGMEHL	7.91	YMDGTMSQV	5.06	RLAPFVYLL	3.57
LLDDLLVSI	7.09	FLWGPRALV	8.25	MLGTHTMEV	7.3	FLLGLIFLL	3.81
ILDKVLVHL	23.6	KVAELVHFL	12.85	MLLAVLYCL	9.16	LLNAFTVTV	4.62
FLIIWQNTM	41.32	KASEKIFYV	19.14	KTWGQYWQV	10.05	FLGYLILGV	4.72
ILNAMIAKI	48.98	KVVEFLAML	28.91	YLSGANLNL	11.01	RLVDDFLLV	5.33
RLSSCVPVA	95.1	FLDRFLSCM	29.39	SLSKILDTV	11.3	ILAKFLHWL	6.69
		MLMAQEALA	36.44	TLMSAMTNL	14.16	SLLSGDWVL	9.08
		ALSVMGVYV	39.45	LLWSFQTSA	15.49	ALLALTSAV	9.8
		SLGWLFLLL	62.17	SVYDFFVWL	30.44	RMPEAAPPV	9.87
				TLDSQVMSL	40.15	SLLQHLIGL	10.34
				FLFLLFFWL	42.03	LLGATCMFV	10.56
				YLEPGPVTA	90.62	ALWPWLLMA	11.75
				VLHWDPETV	93.14	LLGRNSFEV	12.27
						KIFGSLAFL	12.97
						FMVEDETVL	16.5
						MIAVFLPIV	19.54
						FVGEFFTDV	19.75
						TLNDECWPA	20.02
						VLDGLDVLL	22.43
						TLPGYPPHV	23.06
						LLLLTVLTV	23.85
						CQWGRLWQL	24.33
						ALLEIASCL	26.78
						FLALSILVL	30.04
						RLLQETELV	30.47
						ILHNGAYSL	30.71
						VLVPPLPSL	30.78
						LLSDDDVVV	32.87
						VVLGVVFGI	33.45
						KMDAEHPEL	35.44
						CIAEQYHTV	48.36
						HLSTAFARV	49.81
						TIHDSIQYV	50.48
						KVHPVIWSL	57.52
						VLCSIDWFM	58.74
						GLPPDVQRV	64.57
						SVASTITGV	70.61
						MIMVKCWMI	74.82
						GLQLGVQAV	77.31
HLA-A*2402
SYLDSGIHF	30.15	LYATVIHDI	36.85	IYMDGTADF	11.17	KYDCFLHPF	21.58
		NYKRCFPVI	76.24	AFLPWHRLF	36.32	LYVDSLFFL	73.72
				TYACFVSNL	43.49	NYARTEDFF	100.71
				VYFFLPDHL	47.11
HLA-A*0101
YTDFHCQYV	20.14	EVDPIGHLY	20.91	N/A		N/A
YVDFREYEY	11.2	EADPTGHSY	71.37
HLA-A*0301
KINKNPKYK	55.3	SLFRAVITK	12.2	HLFGYSWYK	6.17	NTYASPRFK	29.97
				LIYRRRLMK	7.81	VLRENTSPK	31.21
				ALNFPGSQK	15.05	LASFKSFLK	90.6
				ALLAVGATK	38.81
				RSYVPLAHR	64.02